Nanjing Vcare Won the Title of "Top 20 Chinese Pharmaceutical CRO Enterprises" Again

2024-07-08

On July 4th, the 2024 International Pharmaceutical Service Industry Innovation and Development Conference and the 9th China Pharmaceutical R&D and Innovation Summit (PDI) opened at the Xiong'an Convention and Exhibition Center in Xiong'an New Area. At the conference, the "2024 Ranking List of Chinese Pharmaceutical R&D Strength" was grandly released. Nanjing Vcare once again ranked among the "Top 20 Chinese Pharmaceutical CRO Enterprises" with its solid strength and has maintained the 10th position for three consecutive years.

 

 

Since 2020, Vcare PharmaTech has been listed on this ranking list for five consecutive times, which indicates that the R&D strength, professional level, innovation ability and growth level of Vcare PharmaTech have once again been affirmed and recognized by the industry. It is also an encouragement for Nanjing Vcare to achieve a breakthrough against the odds and maintain strong development potential in the current "cold winter" of the pharmaceutical industry.

With an international perspective, Nanjing Vcare focuses deeply on the R&D and production services covering the whole industrial chain and the whole life cycle of chemical drugs. It spares no effort to build a one-stop CRO/CDMO service platform integrating "chemistry + pharmacy + medicine". We hope that on the road of facilitating the innovative development of the pharmaceutical industry, we can join hands with global pharmaceutical enterprises and new drug R&D institutions to provide customers with integrated services covering the whole industrial chain, including CDMO production and supply from pharmaceutical intermediates to active pharmaceutical ingredients, as well as CRO research and registration from pharmaceutical CMC to clinical trials, so as to comprehensively assist the development of customers.

Prev

Nanjing Vcare Was Certified as the "Nanjing Engineering Technology Research Center in 2024"

Next

Nanjing Vcare Made a Splendid Appearance at CPHI China 2024